{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T16:13:06Z","timestamp":1790179986613,"version":"4.1.0"},"reference-count":195,"publisher":"Oxford University Press (OUP)","issue":"4","license":[{"start":{"date-parts":[[2019,4,1]],"date-time":"2019-04-01T00:00:00Z","timestamp":1554076800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"funder":[{"DOI":"10.13039\/100010661","name":"Horizon 2020 Marie Sklodowska-Curie Innovative Training Networks programme","doi-asserted-by":"publisher","award":["674909"],"award-info":[{"award-number":["674909"]}],"id":[{"id":"10.13039\/100010661","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2019,4,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Objectives<\/jats:title>\n                    <jats:p>Drug product performance in patients with gastrointestinal (GI) diseases can be altered compared to healthy subjects due to pathophysiological changes. In this review, relevant differences in patients with inflammatory bowel diseases, coeliac disease, irritable bowel syndrome and short bowel syndrome are discussed and possible in vitro and in silico tools to predict drug product performance in this patient population are assessed.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Key findings<\/jats:title>\n                    <jats:p>Drug product performance was altered in patients with GI diseases compared to healthy subjects, as assessed in a limited number of studies for some drugs. Underlying causes can be observed pathophysiological alterations such as the differences in GI transit time, the composition of the GI fluids and GI permeability. Additionally, alterations in the abundance of metabolising enzymes and transporter systems were observed. The effect of the GI diseases on each parameter is not always evident as it may depend on the location and the state of the disease. The impact of the pathophysiological change on drug bioavailability depends on the physicochemical characteristics of the drug, the pharmaceutical formulation and drug metabolism. In vitro and in silico methods to predict drug product performance in patients with GI diseases are currently limited but could be a useful tool to improve drug therapy.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Summary<\/jats:title>\n                    <jats:p>Development of suitable in vitro dissolution and in silico models for patients with GI diseases can improve their drug therapy. The likeliness of the models to provide accurate predictions depends on the knowledge of pathophysiological alterations, and thus, further assessment of physiological differences is essential.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1111\/jphp.12928","type":"journal-article","created":{"date-parts":[[2018,5,16]],"date-time":"2018-05-16T03:50:45Z","timestamp":1526442645000},"page":"674-698","source":"Crossref","is-referenced-by-count":90,"title":["Impact of gastrointestinal disease states on oral drug absorption \u2013 implications for formulation design \u2013 a PEARRL review"],"prefix":"10.1093","volume":"71","author":[{"given":"Angela","family":"Effinger","sequence":"first","affiliation":[{"name":"Department of Pharmacy and Pharmacology, University of Bath , Bath,","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caitriona M","family":"O'Driscoll","sequence":"additional","affiliation":[{"name":"School of Pharmacy, University College Cork , Cork,","place":["Ireland"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark","family":"McAllister","sequence":"additional","affiliation":[{"name":"Pfizer Drug Product Design , Sandwich,","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1826-7363","authenticated-orcid":false,"given":"Nikoletta","family":"Fotaki","sequence":"additional","affiliation":[{"name":"Department of Pharmacy and Pharmacology, University of Bath , Bath,","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2019,4,1]]},"reference":[{"key":"2024103012365911000_jphp12928-cit-0001","doi-asserted-by":"crossref","first-page":"233","DOI":"10.2165\/00003088-199936030-00004","article-title":"Drug, meal and formulation interactions influencing drug absorption after oral administration. Clinical implications","volume":"3","author":"Fleisher","year":"1999","journal-title":"Clin Pharmacokinet"},{"key":"2024103012365911000_jphp12928-cit-0002","doi-asserted-by":"crossref","first-page":"1956","DOI":"10.1007\/s11095-008-9645-9","article-title":"Bioavailability and bioequivalence: focus on physiological factors and variability","volume":"8","author":"Karalis","year":"2008","journal-title":"Pharm Res"},{"key":"2024103012365911000_jphp12928-cit-0003","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1111\/j.1365-2036.1997.tb00814.x","article-title":"Review article: drug development in inflammatory bowel disease: budesonide \u2013 a model of targeted therapy","volume":"11","author":"Hamedani","year":"1997","journal-title":"Aliment Pharmacol Ther"},{"key":"2024103012365911000_jphp12928-cit-0004","doi-asserted-by":"crossref","first-page":"2199","DOI":"10.2146\/ajhp120689","article-title":"Drug absorption in celiac disease","volume":"24","author":"Tran","year":"2013","journal-title":"Am J Health Syst Pharm"},{"key":"2024103012365911000_jphp12928-cit-0005","doi-asserted-by":"crossref","first-page":"2029","DOI":"10.1016\/j.clinthera.2014.09.018","article-title":"Antidepressant agents in short bowel syndrome","volume":"12","author":"Faye","year":"2014","journal-title":"Clin Ther"},{"key":"2024103012365911000_jphp12928-cit-0006","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1007\/s13346-013-0185-4","article-title":"Biopharmaceutical considerations and characterizations in development of colon targeted dosage forms for inflammatory bowel disease","volume":"2","author":"Malayandi","year":"2014","journal-title":"Drug Deliv Transl Res"},{"key":"2024103012365911000_jphp12928-cit-0007","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1177\/2050640614548096","article-title":"Colonic motility in ulcerative colitis","volume":"6","author":"Bassotti","year":"2014","journal-title":"United European Gastroenterol J"},{"key":"2024103012365911000_jphp12928-cit-0008","doi-asserted-by":"crossref","first-page":"476","DOI":"10.1002\/jps.24696","article-title":"Literature review of gastrointestinal physiology in the elderly, in pediatric patients, and in patients with gastrointestinal diseases","volume":"2","author":"Bai","year":"2016","journal-title":"J Pharm Sci"},{"key":"2024103012365911000_jphp12928-cit-0009","doi-asserted-by":"crossref","first-page":"1512","DOI":"10.1136\/gut.2005.085373","article-title":"Alterations in intestinal permeability","volume":"10","author":"Arrieta","year":"2006","journal-title":"Gut"},{"key":"2024103012365911000_jphp12928-cit-0010","first-page":"375","article-title":"The impact of the gut microbiota on drug metabolism and clinical outcome","volume":"3","author":"Enright","year":"2016","journal-title":"Yale J Biol Med"},{"key":"2024103012365911000_jphp12928-cit-0011","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.ijpharm.2008.07.009","article-title":"The gastrointestinal microbiota as a site for the biotransformation of drugs","volume":"1\u20132","author":"Sousa","year":"2008","journal-title":"Int J Pharm"},{"key":"2024103012365911000_jphp12928-cit-0012","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1016\/j.ejps.2013.09.008","article-title":"PBPK models for the prediction of in vivo performance of oral dosage forms","volume":"57","author":"Kostewicz","year":"2014","journal-title":"Eur J Pharm Sci"},{"key":"2024103012365911000_jphp12928-cit-0013","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1023\/A:1011984216775","article-title":"Dissolution testing as a prognostic tool for oral drug absorption: immediate release dosage forms","volume":"1","author":"Dressman","year":"1998","journal-title":"Pharm Res"},{"key":"2024103012365911000_jphp12928-cit-0014","doi-asserted-by":"crossref","first-page":"413","DOI":"10.2174\/138945008784221170","article-title":"New insights into inflammatory bowel disease pathophysiology: paving the way for novel therapeutic targets","volume":"5","author":"Stefanelli","year":"2008","journal-title":"Curr Drug Targets"},{"key":"2024103012365911000_jphp12928-cit-0015","doi-asserted-by":"crossref","first-page":"S3","DOI":"10.1097\/01.MIB.0000195385.19268.68","article-title":"Inflammatory bowel disease: epidemiology, pathogenesis, and therapeutic opportunities","volume":"12","author":"Hanauer","year":"2006","journal-title":"Inflamm Bowel Dis"},{"key":"2024103012365911000_jphp12928-cit-0016","doi-asserted-by":"crossref","first-page":"720","DOI":"10.1038\/nrgastro.2015.150","article-title":"The global burden of IBD: from 2015 to 2025","volume":"12","author":"Kaplan","year":"2015","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"2024103012365911000_jphp12928-cit-0017","first-page":"127","article-title":"Gastrointestinal disease and dosage form performance","volume-title":"Oral Drug Absorption","author":"Vladan","year":"2010"},{"key":"2024103012365911000_jphp12928-cit-0018","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1136\/gut.2005.082909","article-title":"The Montreal classification of inflammatory bowel disease: controversies, consensus, and implications","volume":"6","author":"Satsangi","year":"2006","journal-title":"Gut"},{"key":"2024103012365911000_jphp12928-cit-0019","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1093\/gastro\/gou031","article-title":"Histological evaluation in ulcerative colitis","volume":"3","author":"Deroche","year":"2014","journal-title":"Gastroenterol Rep (Oxf)"},{"key":"2024103012365911000_jphp12928-cit-0020","doi-asserted-by":"crossref","first-page":"9458","DOI":"10.3748\/wjg.v20.i28.9458","article-title":"Epidemiology, demographic characteristics and prognostic predictors of ulcerative colitis","volume":"28","author":"Da Silva","year":"2014","journal-title":"World J Gastroenterol"},{"key":"2024103012365911000_jphp12928-cit-0021","doi-asserted-by":"crossref","first-page":"2066","DOI":"10.1056\/NEJMra0804647","article-title":"Inflammatory bowel disease","volume":"21","author":"Abraham","year":"2009","journal-title":"N Engl J Med"},{"key":"2024103012365911000_jphp12928-cit-0022","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1148\/rg.243035120","article-title":"Cross-sectional imaging in Crohn disease","volume":"3","author":"Furukawa","year":"2004","journal-title":"Radiographics"},{"key":"2024103012365911000_jphp12928-cit-0023","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1111\/nmo.12713","article-title":"Regional gastrointestinal transit times in severe ulcerative colitis","volume":"2","author":"Haase","year":"2016","journal-title":"Neurogastroenterol Motil"},{"key":"2024103012365911000_jphp12928-cit-0024","doi-asserted-by":"crossref","first-page":"22","DOI":"10.3109\/00365529009091905","article-title":"Gastrointestinal motility in patients with ulcerative colitis","volume":"172","author":"Rao","year":"1990","journal-title":"Scand J Gastroenterol Suppl"},{"key":"2024103012365911000_jphp12928-cit-0025","doi-asserted-by":"crossref","first-page":"1434","DOI":"10.1023\/A:1026664105112","article-title":"Inflammation does not decrease intraluminal pH in chronic inflammatory bowel disease","volume":"7","author":"Ewe","year":"1999","journal-title":"Dig Dis Sci"},{"key":"2024103012365911000_jphp12928-cit-0026","doi-asserted-by":"crossref","first-page":"1989","DOI":"10.1007\/BF01297074","article-title":"Very low intraluminal colonic pH in patients with active ulcerative colitis","volume":"11","author":"Fallingborg","year":"1993","journal-title":"Dig Dis Sci"},{"key":"2024103012365911000_jphp12928-cit-0027","first-page":"A-682","article-title":"W1229 colonic pH is lower in patients with mild ulcerative colitis compared to normal controls","volume":"5","author":"Bosworth","year":"2009","journal-title":"Gastroenterology"},{"key":"2024103012365911000_jphp12928-cit-0028","doi-asserted-by":"crossref","first-page":"A781","DOI":"10.1016\/S0016-5085(00)85265-8","article-title":"Gut pH and transit time in ulcerative colitis appear sufficient for complete dissolution of pH-dependent 5-ASA-containing capsules","volume":"4","author":"Nugent","year":"2000","journal-title":"Gastroenterology"},{"key":"2024103012365911000_jphp12928-cit-0029","doi-asserted-by":"crossref","first-page":"2594","DOI":"10.1007\/s10620-013-2694-x","article-title":"Small intestinal bacterial overgrowth and orocecal transit time in patients of inflammatory bowel disease","volume":"9","author":"Rana","year":"2013","journal-title":"Dig Dis Sci"},{"key":"2024103012365911000_jphp12928-cit-0030","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1208\/s12249-016-0521-3","article-title":"Assessment of small intestinal transit times in ulcerative colitis and Crohn's disease patients with different disease activity using video capsule endoscopy","volume":"2","author":"Fischer","year":"2017","journal-title":"AAPS PharmSciTech"},{"key":"2024103012365911000_jphp12928-cit-0031","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1016\/0378-5173(88)90249-9","article-title":"Gastrointestinal transit of small tablets in patients with ulcerative colitis","volume":"1\u20133","author":"Hardy","year":"1988","journal-title":"Int J Pharm"},{"key":"2024103012365911000_jphp12928-cit-0032","doi-asserted-by":"crossref","first-page":"886","DOI":"10.1136\/gut.27.8.886","article-title":"Transit of pharmaceutical dosage forms through the small intestine","volume":"8","author":"Davis","year":"1986","journal-title":"Gut"},{"key":"2024103012365911000_jphp12928-cit-0033","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1111\/j.1365-2036.1987.tb00627.x","article-title":"Evaluation of an enteric-coated delayed-release 5-aminosalicylic acid tablet in patients with inflammatory bowel disease","volume":"4","author":"Hardy","year":"1987","journal-title":"Aliment Pharmacol Ther"},{"key":"2024103012365911000_jphp12928-cit-0034","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1002\/jmri.25166","article-title":"Computational postprocessing quantification of small bowel motility using magnetic resonance images in clinical practice: an initial experience","volume":"2","author":"Akerman","year":"2016","journal-title":"J Magn Reson Imaging"},{"key":"2024103012365911000_jphp12928-cit-0035","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1097\/00042737-200605000-00008","article-title":"Colonic propulsive and postprandial motor activity in patients with ulcerative colitis in remission","volume":"5","author":"Bassotti","year":"2006","journal-title":"Eur J Gastroenterol Hepatol"},{"key":"2024103012365911000_jphp12928-cit-0036","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1046\/j.1365-2036.1998.00358.x","article-title":"Gastrointestinal pH profiles in patients with inflammatory bowel disease","volume":"7","author":"Press","year":"1998","journal-title":"Aliment Pharmacol Ther"},{"key":"2024103012365911000_jphp12928-cit-0037","doi-asserted-by":"crossref","first-page":"1620","DOI":"10.1007\/s11095-010-0158-y","article-title":"Characterization of the ascending colon fluids in ulcerative colitis","volume":"8","author":"Vertzoni","year":"2010","journal-title":"Pharm Res"},{"key":"2024103012365911000_jphp12928-cit-0038","first-page":"A681","article-title":"Gastrointestinal pH profiles in ulcerative colitis","volume":"4","author":"Raimundo","year":"1992","journal-title":"Gastroenterology"},{"key":"2024103012365911000_jphp12928-cit-0039","doi-asserted-by":"crossref","first-page":"2141","DOI":"10.1007\/s11095-009-9927-x","article-title":"Characterization of the contents of ascending colon to which drugs are exposed after oral administration to healthy adults","volume":"9","author":"Diakidou","year":"2009","journal-title":"Pharm Res"},{"key":"2024103012365911000_jphp12928-cit-0040","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1046\/j.1365-2036.2003.01426.x","article-title":"A pharmacoscintigraphic evaluation of oral budesonide given as controlled-release (Entocort) capsules","volume":"4","author":"Edsbacker","year":"2003","journal-title":"Aliment Pharmacol Ther"},{"key":"2024103012365911000_jphp12928-cit-0041","doi-asserted-by":"crossref","first-page":"1616","DOI":"10.1016\/j.crohns.2014.03.003","article-title":"Sequential capsule endoscopy of the small bowel for follow-up of patients with known Crohn's disease","volume":"12","author":"Niv","year":"2014","journal-title":"J Crohns Colitis"},{"key":"2024103012365911000_jphp12928-cit-0042","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1097\/00042737-200301000-00012","article-title":"Assessment of orocaecal transit time in different localization of Crohn's disease and its possible influence on clinical response to therapy","volume":"1","author":"Tursi","year":"2003","journal-title":"Eur J Gastroenterol Hepatol"},{"key":"2024103012365911000_jphp12928-cit-0043","first-page":"114","article-title":"Improved localizing method of radiopill in measurement of entire gastrointestinal pH profiles: colonic luminal pH in normal subjects and patients with Crohn's disease","volume":"1","author":"Sasaki","year":"1997","journal-title":"Am J Gastroenterol"},{"key":"2024103012365911000_jphp12928-cit-0044","doi-asserted-by":"crossref","first-page":"702","DOI":"10.1023\/A:1018893409596","article-title":"Small intestinal transit time and intraluminal pH in ileocecal resected patients with Crohn's disease","volume":"4","author":"Fallingborg","year":"1998","journal-title":"Dig Dis Sci"},{"key":"2024103012365911000_jphp12928-cit-0045","doi-asserted-by":"crossref","first-page":"618","DOI":"10.1097\/00054725-200409000-00018","article-title":"Impaired gastric acid and pancreatic enzyme secretion in patients with Crohn's disease may be a consequence of a poor nutritional state","volume":"5","author":"Winter","year":"2004","journal-title":"Inflamm Bowel Dis"},{"key":"2024103012365911000_jphp12928-cit-0046","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1186\/1471-230X-12-175","article-title":"Dyspeptic symptoms and delayed gastric emptying of solids in patients with inactive Crohn's disease","volume":"12","author":"Nobrega","year":"2012","journal-title":"BMC Gastroenterol"},{"key":"2024103012365911000_jphp12928-cit-0047","doi-asserted-by":"crossref","first-page":"1041","DOI":"10.1038\/ajg.2014.104","article-title":"First multicenter study of modified release phosphatidylcholine \u201cLT-02\u201d in ulcerative colitis: a randomized, placebo-controlled trial in mesalazine-refractory courses","volume":"7","author":"Karner","year":"2014","journal-title":"Am J Gastroenterol"},{"key":"2024103012365911000_jphp12928-cit-0048","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1080\/00365520410006233","article-title":"Phosphatidylcholine and lysophosphatidylcholine in intestinal mucus of ulcerative colitis patients. A quantitative approach by nanoelectrospray-tandem mass spectrometry","volume":"8","author":"Ehehalt","year":"2004","journal-title":"Scand J Gastroenterol"},{"key":"2024103012365911000_jphp12928-cit-0049","doi-asserted-by":"crossref","first-page":"1705","DOI":"10.1002\/ibd.20993","article-title":"Alterations of phospholipid concentration and species composition of the intestinal mucus barrier in ulcerative colitis: a clue to pathogenesis","volume":"11","author":"Braun","year":"2009","journal-title":"Inflamm Bowel Dis"},{"key":"2024103012365911000_jphp12928-cit-0050","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1136\/gut.23.4.326","article-title":"Comparison of the composition of faecal fluid in Crohn's disease and ulcerative colitis","volume":"4","author":"Schilli","year":"1982","journal-title":"Gut"},{"key":"2024103012365911000_jphp12928-cit-0051","doi-asserted-by":"crossref","first-page":"751","DOI":"10.1136\/gut.23.9.751","article-title":"Bile acid absorption kinetics in Crohn's disease on elemental diet after oral administration of a stable-isotope tracer with chenodeoxycholic-11, 12-d2 acid","volume":"9","author":"Nishida","year":"1982","journal-title":"Gut"},{"key":"2024103012365911000_jphp12928-cit-0052","doi-asserted-by":"crossref","first-page":"1072","DOI":"10.1136\/gut.20.12.1072","article-title":"Bile acid studies in patients with Crohn's colitis","volume":"12","author":"Rutgeerts","year":"1979","journal-title":"Gut"},{"key":"2024103012365911000_jphp12928-cit-0053","doi-asserted-by":"crossref","first-page":"730","DOI":"10.1136\/gut.18.9.730","article-title":"Bile acid studies in uncomplicated Crohn's disease","volume":"9","author":"Vantrappen","year":"1977","journal-title":"Gut"},{"key":"2024103012365911000_jphp12928-cit-0054","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1155\/2013\/485631","article-title":"Bile acid malabsorption in chronic diarrhea: pathophysiology and treatment","volume":"11","author":"Barkun","year":"2013","journal-title":"Can J Gastroenterol"},{"key":"2024103012365911000_jphp12928-cit-0055","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1080\/00365521.1976.12097178","article-title":"Bile acid metabolism and plasma protein turnover in Crohn's disease","volume":"7","author":"Lenz","year":"1976","journal-title":"Scand J Gastroenterol"},{"key":"2024103012365911000_jphp12928-cit-0056","doi-asserted-by":"crossref","first-page":"1322","DOI":"10.1002\/ibd.21502","article-title":"Bile acid malabsorption in inflammatory bowel disease: assessment by serum markers","volume":"6","author":"Lenicek","year":"2011","journal-title":"Inflamm Bowel Dis"},{"key":"2024103012365911000_jphp12928-cit-0057","doi-asserted-by":"crossref","first-page":"1353","DOI":"10.1007\/BF01536987","article-title":"Organic anions and the diarrhea of inflammatory bowel disease","volume":"11","author":"Vernia","year":"1988","journal-title":"Dig Dis Sci"},{"key":"2024103012365911000_jphp12928-cit-0058","doi-asserted-by":"crossref","first-page":"1076","DOI":"10.1136\/gut.31.9.1076","article-title":"Pancreatic function in Crohn's disease","volume":"9","author":"Hegnh\u00f8j","year":"1990","journal-title":"Gut"},{"key":"2024103012365911000_jphp12928-cit-0059","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1007\/BF02798930","article-title":"Pancreatic function in chronic inflammatory bowel disease","volume":"2\u20133","author":"Angelini","year":"1988","journal-title":"Int J Pancreatol"},{"key":"2024103012365911000_jphp12928-cit-0060","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1007\/978-1-4419-0840-7_2","article-title":"Transporters: importance in drug absorption, distribution, and removal","volume-title":"Enzyme- and Transporter-Based Drug-Drug Interactions: Progress and Future Challenges","author":"Russel","year":"2010"},{"key":"2024103012365911000_jphp12928-cit-0061","doi-asserted-by":"crossref","first-page":"1340","DOI":"10.1016\/j.addr.2012.09.042","article-title":"Intestinal drug transporters: an overview","volume":"10","author":"Estudante","year":"2013","journal-title":"Adv Drug Deliv Rev"},{"key":"2024103012365911000_jphp12928-cit-0062","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1136\/gut.35.3.353","article-title":"Thickness of adherent mucus gel on colonic mucosa in humans and its relevance to colitis","volume":"3","author":"Pullan","year":"1994","journal-title":"Gut"},{"key":"2024103012365911000_jphp12928-cit-0063","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1038\/nrd3028","article-title":"Membrane transporters in drug development","volume":"3","author":"The International Transporter Consortium","year":"2010","journal-title":"Nat Rev Drug Discov"},{"key":"2024103012365911000_jphp12928-cit-0064","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1002\/ibd.20030","article-title":"Efflux transporters in ulcerative colitis: decreased expression of BCRP (ABCG2) and Pgp (ABCB1)","volume":"3","author":"Englund","year":"2007","journal-title":"Inflamm Bowel Dis"},{"key":"2024103012365911000_jphp12928-cit-0065","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1016\/j.prp.2013.12.010","article-title":"Expression of selected cytochrome P450 isoforms and of cooperating enzymes in colorectal tissues in selected pathological conditions","volume":"4","author":"Plewka","year":"2014","journal-title":"Pathol Res Pract"},{"key":"2024103012365911000_jphp12928-cit-0066","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1136\/gut.50.3.307","article-title":"Augmented increase in tight junction permeability by luminal stimuli in the non-inflamed ileum of Crohn's disease","volume":"3","author":"S\u00f6derholm","year":"2002","journal-title":"Gut"},{"key":"2024103012365911000_jphp12928-cit-0067","first-page":"151","article-title":"Small bowel and colonic permeability to 51Cr-EDTA in patients with active inflammatory bowel disease","volume":"2","author":"Jenkins","year":"1988","journal-title":"Clin Invest Med"},{"key":"2024103012365911000_jphp12928-cit-0068","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1007\/BF01536764","article-title":"Intestinal permeability in gastrointestinal disorders. Use of oral [99mtc]Dtpa","volume":"2","author":"Resnick","year":"1990","journal-title":"Dig Dis Sci"},{"key":"2024103012365911000_jphp12928-cit-0069","doi-asserted-by":"crossref","first-page":"582","DOI":"10.1007\/BF01540405","article-title":"Relationship between intestinal permeability to [51Cr]EDTA and inflammatory activity in asymptomatic patients with Crohn's disease","volume":"5","author":"Pironi","year":"1990","journal-title":"Dig Dis Sci"},{"key":"2024103012365911000_jphp12928-cit-0070","first-page":"1891","article-title":"Increased gastric and intestinal permeability in patients with Crohn's disease","volume":"10","author":"Wyatt","year":"1997","journal-title":"Am J Gastroenterol"},{"key":"2024103012365911000_jphp12928-cit-0071","first-page":"143","article-title":"Intestinal permeability tests in coeliac disease","volume":"3\u20134","author":"Johnston","year":"2001","journal-title":"Clin Lab"},{"key":"2024103012365911000_jphp12928-cit-0072","doi-asserted-by":"crossref","first-page":"1399","DOI":"10.3748\/wjg.14.1399","article-title":"Intestinal permeability and its association with the patient and disease characteristics in Crohn's disease","volume":"9","author":"Benjamin","year":"2008","journal-title":"World J Gastroenterol"},{"key":"2024103012365911000_jphp12928-cit-0073","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1038\/mi.2010.5","article-title":"Multiple facets of intestinal permeability and epithelial handling of dietary antigens","volume":"3","author":"Menard","year":"2010","journal-title":"Mucosal Immunol"},{"key":"2024103012365911000_jphp12928-cit-0074","doi-asserted-by":"crossref","first-page":"2312","DOI":"10.1007\/s10620-005-3053-3","article-title":"A higher dose requirement of tacrolimus in active Crohn's disease may be related to a high intestinal P-glycoprotein content","volume":"12","author":"Buchman","year":"2005","journal-title":"Dig Dis Sci"},{"key":"2024103012365911000_jphp12928-cit-0075","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1016\/S0011-393X(98)85095-9","article-title":"Expression of intestinal drug-metabolizing enzymes in patients with chronic inflammatory bowel disease","volume":"8","author":"Klotz","year":"1998","journal-title":"Curr Ther Res"},{"key":"2024103012365911000_jphp12928-cit-0076","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1136\/gut.32.1.46","article-title":"Impaired sulphation of phenol by the colonic mucosa in quiescent and active ulcerative colitis","volume":"1","author":"Ramakrishna","year":"1991","journal-title":"Gut"},{"key":"2024103012365911000_jphp12928-cit-0077","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1046\/j.1365-2125.1998.00808.x","article-title":"Paracetamol metabolism in patients with ulcerative colitis","volume":"5","author":"Haderslev","year":"1998","journal-title":"Br J Clin Pharmacol"},{"key":"2024103012365911000_jphp12928-cit-0078","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1097\/00054725-200608000-00011","article-title":"Impact of inflammation on the duodenal mRNA expression of CYP3A and P-glycoprotein in children with Crohn's disease","volume":"8","author":"Fakhoury","year":"2006","journal-title":"Inflamm Bowel Dis"},{"key":"2024103012365911000_jphp12928-cit-0079","doi-asserted-by":"crossref","first-page":"804","DOI":"10.1097\/MIB.0000000000001062","article-title":"CYP3A4 activity is markedly lower in patients with Crohn's disease","volume":"5","author":"Wilson","year":"2017","journal-title":"Inflamm Bowel Dis"},{"key":"2024103012365911000_jphp12928-cit-0080","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1053\/j.gastro.2016.10.012","article-title":"Roles for intestinal bacteria, viruses, and fungi in pathogenesis of inflammatory bowel diseases and therapeutic approaches","volume":"2","author":"Sartor","year":"2017","journal-title":"Gastroenterology"},{"key":"2024103012365911000_jphp12928-cit-0081","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1038\/nature08821","article-title":"A human gut microbial gene catalogue established by metagenomic sequencing","volume":"7285","author":"Qin","year":"2010","journal-title":"Nature"},{"key":"2024103012365911000_jphp12928-cit-0082","doi-asserted-by":"crossref","first-page":"1081","DOI":"10.3389\/fmicb.2016.01081","article-title":"The gut microbiota in immune-mediated inflammatory diseases","volume":"7","author":"Forbes","year":"2016","journal-title":"Front Microbiol"},{"key":"2024103012365911000_jphp12928-cit-0083","doi-asserted-by":"crossref","first-page":"R79","DOI":"10.1186\/gb-2012-13-9-r79","article-title":"Dysfunction of the intestinal microbiome in inflammatory bowel disease and treatment","volume":"9","author":"Morgan","year":"2012","journal-title":"Genome Biol"},{"key":"2024103012365911000_jphp12928-cit-0084","doi-asserted-by":"crossref","first-page":"1275","DOI":"10.1136\/gutjnl-2013-304833","article-title":"A decrease of the butyrate-producing species Roseburia hominis and Faecalibacterium prausnitzii defines dysbiosis in patients with ulcerative colitis","volume":"8","author":"Machiels","year":"2014","journal-title":"Gut"},{"key":"2024103012365911000_jphp12928-cit-0085","doi-asserted-by":"crossref","first-page":"2641","DOI":"10.1007\/BF02220454","article-title":"Bacterial enzymes used for colon-specific drug delivery are decreased in active Crohn's disease","volume":"12","author":"Carrette","year":"1995","journal-title":"Dig Dis Sci"},{"key":"2024103012365911000_jphp12928-cit-0086","doi-asserted-by":"crossref","first-page":"2146","DOI":"10.1128\/aem.56.7.2146-2151.1990","article-title":"Azoreductase activity of anaerobic bacteria isolated from human intestinal microflora","volume":"7","author":"Rafii","year":"1990","journal-title":"Appl Environ Microbiol"},{"key":"2024103012365911000_jphp12928-cit-0087","doi-asserted-by":"crossref","first-page":"684","DOI":"10.1002\/ibd.21108","article-title":"Butyrate utilization by the colonic mucosa in inflammatory bowel diseases: a transport deficiency","volume":"4","author":"Thibault","year":"2010","journal-title":"Inflamm Bowel Dis"},{"key":"2024103012365911000_jphp12928-cit-0088","doi-asserted-by":"crossref","first-page":"14805","DOI":"10.3748\/wjg.v20.i40.14805","article-title":"Intestinal microbiota pathogenesis and fecal microbiota transplantation for inflammatory bowel disease","volume":"40","author":"Wang","year":"2014","journal-title":"World J Gastroenterol"},{"key":"2024103012365911000_jphp12928-cit-0089","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1016\/j.jiac.2015.07.010","article-title":"Intestinal microbiota and ulcerative colitis","volume":"11","author":"Ohkusa","year":"2015","journal-title":"J Infect Chemother"},{"key":"2024103012365911000_jphp12928-cit-0090","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1042\/cs0740071","article-title":"Degradation by bacterial enzymes of colonic mucus from normal subjects and patients with inflammatory bowel disease: the role of sialic acid metabolism and the detection of a novel O-acetylsialic acid esterase","volume":"1","author":"Corfield","year":"1988","journal-title":"Clin Sci (Lond)"},{"key":"2024103012365911000_jphp12928-cit-0091","first-page":"1219","article-title":"Recent advances in characterizing the gastrointestinal microbiome in Crohn's disease: a systematic review","volume":"6","author":"Wright","year":"2015","journal-title":"Inflamm Bowel Dis"},{"key":"2024103012365911000_jphp12928-cit-0092","doi-asserted-by":"crossref","first-page":"921","DOI":"10.1111\/j.1651-2227.2000.tb00408.x","article-title":"Gastric emptying of solids is delayed in celiac disease and normalizes after gluten withdrawal","volume":"8","author":"Perri","year":"2000","journal-title":"Acta Paediatr"},{"key":"2024103012365911000_jphp12928-cit-0093","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1146\/annurev.med.57.051804.122404","article-title":"Celiac disease","volume":"57","author":"Green","year":"2006","journal-title":"Annu Rev Med"},{"key":"2024103012365911000_jphp12928-cit-0094","doi-asserted-by":"crossref","first-page":"653","DOI":"10.4253\/wjge.v8.i18.653","article-title":"Recommendations to quantify villous atrophy in video capsule endoscopy images of celiac disease patients","volume":"18","author":"Ciaccio","year":"2016","journal-title":"World J Gastrointest Endosc"},{"key":"2024103012365911000_jphp12928-cit-0095","doi-asserted-by":"crossref","first-page":"2100","DOI":"10.1023\/A:1018878703699","article-title":"Gluten-free diet normalizes mouth-to-cecum transit of a caloric meal in adult patients with celiac disease","volume":"10","author":"Battaglia","year":"1997","journal-title":"Dig Dis Sci"},{"key":"2024103012365911000_jphp12928-cit-0096","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1042\/cs0720217","article-title":"Delayed postprandial plasma bile acid response in coeliac patients with slow mouth-caecum transit","volume":"2","author":"Spiller","year":"1987","journal-title":"Clin Sci (Lond)"},{"key":"2024103012365911000_jphp12928-cit-0097","first-page":"277","article-title":"Abnormal colonic transit time in untreated celiac sprue","volume":"5","author":"Bai","year":"1995","journal-title":"Acta Gastroenterol Latinoam"},{"key":"2024103012365911000_jphp12928-cit-0098","first-page":"1044","article-title":"Gastric emptying of realistic meals with and without gluten in patients with coeliac disease. Effect of jejunal mucosal recovery","volume":"10","author":"Benini","year":"2001","journal-title":"Scand J Gastroenterol"},{"key":"2024103012365911000_jphp12928-cit-0099","first-page":"269","article-title":"Gastric emptying and plasma neurotensin levels in untreated celiac patients","volume":"3","author":"Bardella","year":"2000","journal-title":"Scand J Gastroenterol"},{"key":"2024103012365911000_jphp12928-cit-0100","first-page":"1167","article-title":"Evaluation of gastric and small bowel transit times in coeliac disease with the small bowel PillCam(R): a single centre study in a non gluten-free diet adult italian population with coeliac disease","volume":"9","author":"Urgesi","year":"2013","journal-title":"Eur Rev Med Pharmacol Sci"},{"key":"2024103012365911000_jphp12928-cit-0101","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1111\/j.1365-2982.1995.tb00232.x","article-title":"Oesophageal motility in adult coeliac disease","volume":"4","author":"Usai","year":"1995","journal-title":"Neurogastroenterol Motil"},{"key":"2024103012365911000_jphp12928-cit-0102","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1042\/cs0630373","article-title":"Altered jejunal surface pH in coeliac disease: its effect on propranolol and folic acid absorption","volume":"4","author":"Kitis","year":"1982","journal-title":"Clin Sci (Lond)"},{"key":"2024103012365911000_jphp12928-cit-0103","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1136\/gut.19.8.735","article-title":"Acid microclimate in coeliac and Crohn's disease: a model for folate malabsorption","volume":"8","author":"Lucas","year":"1978","journal-title":"Gut"},{"key":"2024103012365911000_jphp12928-cit-0104","doi-asserted-by":"crossref","first-page":"313","DOI":"10.3109\/00365527109181126","article-title":"Intraluminal pH of duodenum and jejunum in fasting subjects with normal and abnormal gastric or pancreatic function","volume":"4","author":"Benn","year":"1971","journal-title":"Scand J Gastroenterol"},{"key":"2024103012365911000_jphp12928-cit-0105","doi-asserted-by":"crossref","first-page":"796","DOI":"10.1136\/gut.32.7.796","article-title":"Exocrine pancreatic function in children with coeliac disease before and after a gluten free diet","volume":"7","author":"Carroccio","year":"1991","journal-title":"Gut"},{"key":"2024103012365911000_jphp12928-cit-0106","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1046\/j.1365-2036.2000.014s2058.x","article-title":"Review article: the \u2018mechanical pumps\u2019 and the enterohepatic circulation of bile acids\u2013defects in coeliac disease","volume":"14","author":"Lanzini","year":"2000","journal-title":"Aliment Pharmacol Ther"},{"key":"2024103012365911000_jphp12928-cit-0107","doi-asserted-by":"crossref","first-page":"991","DOI":"10.1016\/S0140-6736(71)91387-0","article-title":"Gallbladder inertia and sluggish enterohepatic circulation of bile-salts in c\u0153liac disease","volume":"7707","author":"Low-Beer","year":"1971","journal-title":"The Lancet"},{"key":"2024103012365911000_jphp12928-cit-0108","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1016\/S0016-5085(85)80145-1","article-title":"Increased biliary lipid secretion in celiac disease","volume":"1","author":"Vuoristo","year":"1985","journal-title":"Gastroenterology"},{"key":"2024103012365911000_jphp12928-cit-0109","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1136\/gut.31.2.153","article-title":"Signs of increased leakage over the jejunal mucosa during gliadin challenge of patients with coeliac disease","volume":"2","author":"Lavo","year":"1990","journal-title":"Gut"},{"key":"2024103012365911000_jphp12928-cit-0110","first-page":"197","article-title":"Gut permeability to human alpha-lactalbumin, beta-lactoglobulin, mannitol, and lactulose in celiac disease","volume":"2","author":"Kuitunen","year":"1996","journal-title":"J Pediatr Gastroenterol Nutr"},{"key":"2024103012365911000_jphp12928-cit-0111","doi-asserted-by":"crossref","first-page":"809","DOI":"10.1007\/BF01318423","article-title":"Small intestinal permeability to mannitol, lactulose, and polyethylene glycol 400 in celiac disease","volume":"9","author":"Ukabam","year":"1984","journal-title":"Dig Dis Sci"},{"key":"2024103012365911000_jphp12928-cit-0112","doi-asserted-by":"crossref","first-page":"1105","DOI":"10.1590\/S0100-879X2008001200010","article-title":"Gut permeability to lactulose and mannitol differs in treated Crohn's disease and celiac disease patients and healthy subjects","volume":"12","author":"Vilela","year":"2008","journal-title":"Braz J Med Biol Res"},{"key":"2024103012365911000_jphp12928-cit-0113","doi-asserted-by":"crossref","first-page":"630","DOI":"10.3109\/00365529409092484","article-title":"Comparison of four markers of intestinal permeability in control subjects and patients with coeliac disease","volume":"7","author":"Bjarnason","year":"1994","journal-title":"Scand J Gastroenterol"},{"key":"2024103012365911000_jphp12928-cit-0114","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1203\/PDR.0b013e3181e5bc96","article-title":"Increased expression of hypoxia-inducible factor 1[Agr] in coeliac disease","volume":"2","author":"Vannay","year":"2010","journal-title":"Pediatr Res"},{"key":"2024103012365911000_jphp12928-cit-0115","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/S0009-9236(96)90022-3","article-title":"Decreased intestinal CYP3A in celiac disease: reversal after successful gluten-free diet: a potential source of interindividual variability in first-pass drug metabolism","volume":"1","author":"Lang","year":"1996","journal-title":"Clin Pharmacol Ther"},{"key":"2024103012365911000_jphp12928-cit-0116","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1046\/j.1365-2125.2001.01370.x","article-title":"Enterocytic CYP3A4 in a paediatric population: developmental changes and the effect of coeliac disease and cystic fibrosis","volume":"5","author":"Johnson","year":"2001","journal-title":"Br J Clin Pharmacol"},{"key":"2024103012365911000_jphp12928-cit-0117","doi-asserted-by":"crossref","first-page":"1461","DOI":"10.1007\/s10620-015-4020-2","article-title":"Gut microbiota and celiac disease","volume":"6","author":"Marasco","year":"2016","journal-title":"Dig Dis Sci"},{"key":"2024103012365911000_jphp12928-cit-0118","doi-asserted-by":"crossref","first-page":"902","DOI":"10.1111\/apt.12681","article-title":"Letter: coeliac disease and small intestinal bacterial overgrowth \u2013 is dysmotility the missing link?","volume":"8","author":"Mooney","year":"2014","journal-title":"Aliment Pharmacol Ther"},{"key":"2024103012365911000_jphp12928-cit-0119","first-page":"171","article-title":"Small intestinal bacterial overgrowth prevalence in celiac disease patients is similar in healthy subjects and lower in irritable bowel syndrome patients","volume":"2","author":"Lasa","year":"2015","journal-title":"Rev Gastroenterol Mex"},{"key":"2024103012365911000_jphp12928-cit-0120","first-page":"A579","article-title":"Small intestinal bacterial overgrowth and gastrointestinal symptoms in celiac disease patients and in patients receiving proton pomp inhibitors","volume":"1","author":"Zwolinska-Wcislo","year":"2013","journal-title":"United European Gastroenterol J"},{"key":"2024103012365911000_jphp12928-cit-0121","doi-asserted-by":"crossref","first-page":"e13028","DOI":"10.1111\/nmo.13028","article-title":"Small intestinal bacterial overgrowth and celiac disease: a systematic review with pooled-data analysis","volume":"29","author":"Losurdo","year":"2017","journal-title":"Neurogastroenterol Motil"},{"key":"2024103012365911000_jphp12928-cit-0122","doi-asserted-by":"crossref","first-page":"1770","DOI":"10.1136\/gut.2007.119446","article-title":"Guidelines on the irritable bowel syndrome: mechanisms and practical management","volume":"12","author":"Spiller","year":"2007","journal-title":"Gut"},{"key":"2024103012365911000_jphp12928-cit-0123","first-page":"333","article-title":"Gastrointestinal pH profile in subjects with irritable bowel syndrome","volume":"4","author":"Lalezari","year":"2012","journal-title":"Ann Gastroenterol"},{"key":"2024103012365911000_jphp12928-cit-0124","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1136\/gut.24.5.405","article-title":"Irritable bowel syndrome: relationship of disorders in the transit of a single solid meal to symptom patterns","volume":"5","author":"Cann","year":"1983","journal-title":"Gut"},{"key":"2024103012365911000_jphp12928-cit-0125","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1111\/j.1365-2036.2009.04081.x","article-title":"Systematic review: the prevalence of idiopathic bile acid malabsorption as diagnosed by SeHCAT scanning in patients with diarrhoea-predominant irritable bowel syndrome","volume":"7","author":"Wedlake","year":"2009","journal-title":"Aliment Pharmacol Ther"},{"key":"2024103012365911000_jphp12928-cit-0126","doi-asserted-by":"crossref","first-page":"1330","DOI":"10.1111\/nmo.12829","article-title":"Interplay between bile acid metabolism and microbiota in irritable bowel syndrome","volume":"9","author":"Dior","year":"2016","journal-title":"Neurogastroenterol Motil"},{"key":"2024103012365911000_jphp12928-cit-0127","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1111\/j.1365-2982.2007.00925.x","article-title":"Intestinal permeability and irritable bowel syndrome","volume":"7","author":"Camilleri","year":"2007","journal-title":"Neurogastroenterol Motil"},{"key":"2024103012365911000_jphp12928-cit-0128","doi-asserted-by":"crossref","first-page":"2922","DOI":"10.1007\/s10620-009-1094-8","article-title":"Subjects with diarrhea-predominant IBS have increased rectal permeability responsive to tryptase","volume":"10","author":"Lee","year":"2010","journal-title":"Dig Dis Sci"},{"key":"2024103012365911000_jphp12928-cit-0129","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1111\/j.1365-2982.2011.01803.x","article-title":"Distinct microbial populations exist in the mucosa-associated microbiota of sub-groups of irritable bowel syndrome","volume":"1","author":"Parkes","year":"2012","journal-title":"Neurogastroenterol Motil"},{"key":"2024103012365911000_jphp12928-cit-0130","doi-asserted-by":"crossref","first-page":"997","DOI":"10.1136\/gutjnl-2011-301501","article-title":"An irritable bowel syndrome subtype defined by species-specific alterations in faecal microbiota","volume":"7","author":"Jeffery","year":"2012","journal-title":"Gut"},{"key":"2024103012365911000_jphp12928-cit-0131","doi-asserted-by":"crossref","first-page":"1792","DOI":"10.1053\/j.gastro.2011.07.043","article-title":"Global and deep molecular analysis of microbiota signatures in fecal samples from patients with irritable bowel syndrome","volume":"5","author":"Rajilic-Stojanovic","year":"2011","journal-title":"Gastroenterology"},{"key":"2024103012365911000_jphp12928-cit-0132","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1111\/j.1572-0241.2005.40312.x","article-title":"Analysis of the fecal microbiota of irritable bowel syndrome patients and healthy controls with real-time PCR","volume":"2","author":"Malinen","year":"2005","journal-title":"Am J Gastroenterol"},{"key":"2024103012365911000_jphp12928-cit-0133","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1007\/s11894-016-0511-3","article-title":"Management and complications of short bowel syndrome: an updated review","volume":"7","author":"Carroll","year":"2016","journal-title":"Curr Gastroenterol Rep"},{"key":"2024103012365911000_jphp12928-cit-0134","doi-asserted-by":"crossref","first-page":"1707","DOI":"10.1016\/j.clnu.2016.09.028","article-title":"Intestinal microbiota in adult patients with short bowel syndrome: preliminary results from a pilot study","volume":"36","author":"Boccia","year":"2016","journal-title":"Clin Nutr"},{"key":"2024103012365911000_jphp12928-cit-0135","doi-asserted-by":"crossref","first-page":"951","DOI":"10.2165\/00003088-200443140-00001","article-title":"Enteral drug absorption in patients with short small bowel: a review","volume":"14","author":"Severijnen","year":"2004","journal-title":"Clin Pharmacokinet"},{"key":"2024103012365911000_jphp12928-cit-0136","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1016\/j.cgh.2005.10.002","article-title":"Short bowel syndrome and intestinal failure: consensus definitions and overview","volume":"1","author":"O'keefe","year":"2006","journal-title":"Clin Gastroenterol Hepatol"},{"key":"2024103012365911000_jphp12928-cit-0137","doi-asserted-by":"crossref","first-page":"1481","DOI":"10.1089\/jpm.2006.9.1481","article-title":"A review of short bowel syndrome and palliation: a case report and medication guideline","volume":"6","author":"Broadbent","year":"2006","journal-title":"J Palliat Med"},{"key":"2024103012365911000_jphp12928-cit-0138","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1177\/0148607107031003240","article-title":"Noninvasive measurement of transit time in short bowel syndrome","volume":"3","author":"Compher","year":"2007","journal-title":"JPEN J Parenter Enteral Nutr"},{"key":"2024103012365911000_jphp12928-cit-0139","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1007\/BF01308059","article-title":"Fat digestion in patients with bile acid malabsorption but minimal steatorrhea","volume":"5","author":"Mansbach","year":"1980","journal-title":"Dig Dis Sci"},{"key":"2024103012365911000_jphp12928-cit-0140","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1136\/gut.27.1.66","article-title":"Ileal resection: effect of cimetidine and taurine on intrajejunal bile acid precipitation and lipid solubilisation","volume":"1","author":"Fitzpatrick","year":"1986","journal-title":"Gut"},{"key":"2024103012365911000_jphp12928-cit-0141","doi-asserted-by":"crossref","first-page":"1314","DOI":"10.1172\/JCI105823","article-title":"Bile salt and micellar fat concentration in proximal small bowel contents of ileectomy patients","volume":"6","author":"Van Deest","year":"1968","journal-title":"J Clin Invest"},{"issue":"Suppl.","key":"2024103012365911000_jphp12928-cit-0142","first-page":"38S","article-title":"Pharmacologic management of diarrhea in patients with short bowel syndrome","volume":"1","author":"Kumpf","year":"2014","journal-title":"JPEN J Parenter Enteral Nutr"},{"key":"2024103012365911000_jphp12928-cit-0143","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1016\/j.bpg.2016.02.011","article-title":"Definitions of intestinal failure and the short bowel syndrome","volume":"2","author":"Pironi","year":"2016","journal-title":"Best Pract Res Clin Gastroenterol"},{"key":"2024103012365911000_jphp12928-cit-0144","doi-asserted-by":"crossref","first-page":"918","DOI":"10.1016\/S0016-5085(72)80109-4","article-title":"Role of bile acid malabsorption in pathogenesis of diarrhea and steatorrhea in patients with ileal resection","volume":"5","author":"Hofmann","year":"1972","journal-title":"Gastroenterology"},{"issue":"Suppl.","key":"2024103012365911000_jphp12928-cit-0145","first-page":"14s","article-title":"Pathophysiology of short bowel syndrome: considerations of resected and residual anatomy","volume":"1","author":"Tappenden","year":"2014","journal-title":"JPEN J Parenter Enteral Nutr"},{"issue":"Suppl.","key":"2024103012365911000_jphp12928-cit-0146","first-page":"23s","article-title":"Intestinal adaptation following resection","volume":"1","author":"Tappenden","year":"2014","journal-title":"JPEN J Parenter Enteral Nutr"},{"key":"2024103012365911000_jphp12928-cit-0147","doi-asserted-by":"crossref","first-page":"922","DOI":"10.1093\/ajcn\/75.5.922","article-title":"Distribution of the H+\/peptide transporter PepT1 in human intestine: up-regulated expression in the colonic mucosa of patients with short-bowel syndrome","volume":"5","author":"Ziegler","year":"2002","journal-title":"Am J Clin Nutr"},{"key":"2024103012365911000_jphp12928-cit-0148","doi-asserted-by":"crossref","first-page":"G116","DOI":"10.1152\/ajpgi.90657.2008","article-title":"Morphological adaptation with preserved proliferation\/transporter content in the colon of patients with short bowel syndrome","volume":"1","author":"Joly","year":"2009","journal-title":"Am J Physiol Gastrointest Liver Physiol"},{"key":"2024103012365911000_jphp12928-cit-0149","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1016\/1359-6446(96)10039-8","article-title":"Physicochemical and drug-delivery considerations for oral drug bioavailability","volume":"11","author":"Helen Chan","year":"1996","journal-title":"Drug Discov Today"},{"key":"2024103012365911000_jphp12928-cit-0150","doi-asserted-by":"crossref","first-page":"277","DOI":"10.2174\/1568026013395100","article-title":"Physicochemical profiling (solubility, permeability and charge state)","volume":"4","author":"Avdeef","year":"2001","journal-title":"Curr Top Med Chem"},{"key":"2024103012365911000_jphp12928-cit-0151","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1093\/jac\/1.1.39","article-title":"The absorption of antibiotics in adult patients with coeliac disease","volume":"1","author":"Parsons","year":"1975","journal-title":"J Antimicrob Chemother"},{"key":"2024103012365911000_jphp12928-cit-0152","first-page":"391","volume-title":"Proposal to waive in vivo bioequivalence requirements for WHO model list of essential medicines immediate-release, solid oral dosage forms","author":"World Health Organization","year":"2006"},{"key":"2024103012365911000_jphp12928-cit-0153","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1111\/j.1365-2125.1983.tb02147.x","article-title":"The absorption and conjugation of methyldopa in patients with coeliac and Crohn's diseases during treatment","volume":"1","author":"Renwick","year":"1983","journal-title":"Br J Clin Pharmacol"},{"key":"2024103012365911000_jphp12928-cit-0154","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1208\/s12248-012-9439-1","article-title":"Pharmacokinetics of levodopa, carbidopa, and 3-O-Methyldopa Following 16-hour jejunal infusion of levodopa-carbidopa intestinal gel in advanced Parkinson's disease patients","volume":"2","author":"Nyholm","year":"2013","journal-title":"AAPS J"},{"key":"2024103012365911000_jphp12928-cit-0155","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1002\/jps.2600810105","article-title":"Influence of D-glucose-induced water absorption on rat jejunal uptake of two passively absorbed drugs","volume":"1","author":"Lu","year":"1992","journal-title":"J Pharm Sci"},{"key":"2024103012365911000_jphp12928-cit-0156","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1038\/clpt.1981.153","article-title":"Acetaminophen absorption and metabolism in celiac disease and Crohn's disease","volume":"2","author":"Holt","year":"1981","journal-title":"Clin Pharmacol Ther"},{"key":"2024103012365911000_jphp12928-cit-0157","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1111\/j.1365-2125.1995.tb04457.x","article-title":"Serum drug concentrations after oral administration of paracetamol to patients with surgical resection of the gastrointestinal tract","volume":"3","author":"Ueno","year":"1995","journal-title":"Br J Clin Pharmacol"},{"key":"2024103012365911000_jphp12928-cit-0158","volume-title":"Exploring QSAR: Hydrophobic, Electronic, and Steric Constants","author":"Hansch","year":"1995"},{"key":"2024103012365911000_jphp12928-cit-0159","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1046\/j.1365-2036.2003.01652.x","article-title":"High variation of tioguanine absorption in patients with chronic active Crohn's disease","volume":"2","author":"Deibert","year":"2003","journal-title":"Aliment Pharmacol Ther"},{"key":"2024103012365911000_jphp12928-cit-0160","doi-asserted-by":"crossref","first-page":"1098","DOI":"10.1021\/jm901371v","article-title":"Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination","volume":"3","author":"Varma","year":"2010","journal-title":"J Med Chem"},{"key":"2024103012365911000_jphp12928-cit-0161","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1002\/hep.26208","article-title":"High lipophilicity and high daily dose of oral medications are associated with significant risk for drug-induced liver injury","volume":"1","author":"Chen","year":"2013","journal-title":"Hepatology"},{"key":"2024103012365911000_jphp12928-cit-0162","doi-asserted-by":"crossref","first-page":"794","DOI":"10.1136\/bmj.2.6039.794","article-title":"Plasma levels of propranolol in treated patients with coeliac disease and patients with Crohn's disease","volume":"6039","author":"Schneider","year":"1976","journal-title":"Br Med J"},{"key":"2024103012365911000_jphp12928-cit-0163","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1002\/jps.2600820214","article-title":"pH-metric log P. II: refinement of partition coefficients and ionization constants of multiprotic substances","volume":"2","author":"Avdeef","year":"1993","journal-title":"J Pharm Sci"},{"key":"2024103012365911000_jphp12928-cit-0164","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1136\/gut.17.2.139","article-title":"Absorption of propranolol and practolol in coeliac disease","volume":"2","author":"Parsons","year":"1976","journal-title":"Gut"},{"key":"2024103012365911000_jphp12928-cit-0165","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1042\/cs0630081","article-title":"Propranolol absorption in untreated coeliac disease","volume":"1","author":"Sandle","year":"1982","journal-title":"Clin Sci (Lond)"},{"key":"2024103012365911000_jphp12928-cit-0166","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1016\/j.amjmed.2011.09.003","article-title":"Celiac disease and hypothyroidism","volume":"3","author":"Collins","year":"2012","journal-title":"Am J Med"},{"key":"2024103012365911000_jphp12928-cit-0167","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1021\/mp034006h","article-title":"Molecular properties of WHO essential drugs and provisional biopharmaceutical classification","volume":"1","author":"Kasim","year":"2004","journal-title":"Mol Pharm"},{"key":"2024103012365911000_jphp12928-cit-0168","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1111\/j.1365-2036.1987.tb00639.x","article-title":"Prednisolone absorption in inflammatory bowel disease: correlation with anatomical site and extent","volume":"5","author":"Rodrigues","year":"1987","journal-title":"Aliment Pharmacol Ther"},{"key":"2024103012365911000_jphp12928-cit-0169","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1136\/gut.24.3.182","article-title":"Absorption of prednisolone in patients with Crohn's disease","volume":"3","author":"Shaffer","year":"1983","journal-title":"Gut"},{"key":"2024103012365911000_jphp12928-cit-0170","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1159\/000198583","article-title":"Serum prednisolone levels in Crohn's disease and coeliac disease following oral prednisolone administration","volume":"6","author":"Tanner","year":"1981","journal-title":"Digestion"},{"key":"2024103012365911000_jphp12928-cit-0171","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1007\/BF03189406","article-title":"Prednisolone absorption in coeliac disease","volume":"2","author":"Pickup","year":"1979","journal-title":"Eur J Drug Metab Pharmacokinet"},{"key":"2024103012365911000_jphp12928-cit-0172","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/j.ejpb.2016.02.002","article-title":"Effects of gastric pH on oral drug absorption: in vitro assessment using a dissolution\/permeation system reflecting the gastric dissolution process","volume":"101","author":"Kataoka","year":"2016","journal-title":"Eur J Pharm Biopharm"},{"key":"2024103012365911000_jphp12928-cit-0173","first-page":"21","article-title":"Drug transport mechanisms across the intestinal epithelium","volume-title":"Oral Drug Absorption","author":"Ungell","year":"2010"},{"key":"2024103012365911000_jphp12928-cit-0174","volume-title":"Clarke's Analysis of Drugs & Poisons: In Pharmaceuticals, Body Fluids and Postmortem Material","author":"Moffat","year":"2003"},{"key":"2024103012365911000_jphp12928-cit-0175","first-page":"725","article-title":"Intestinal absorption of folic acid \u2013 new physiologic & molecular aspects","volume":"5","author":"Milman","year":"2012","journal-title":"Indian J Med Res"},{"key":"2024103012365911000_jphp12928-cit-0176","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1007\/BF00562942","article-title":"Pharmacokinetics of salicylate and indomethacin in coeliac disease","volume":"6","author":"Parsons","year":"1977","journal-title":"Eur J Clin Pharmacol"},{"key":"2024103012365911000_jphp12928-cit-0177","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1177\/1060028014526700","article-title":"Absorption and efficacy of acetylsalicylic acid in patients with short bowel syndrome","volume":"6","author":"Faye","year":"2014","journal-title":"Ann Pharmacother"},{"key":"2024103012365911000_jphp12928-cit-0178","doi-asserted-by":"crossref","first-page":"137","DOI":"10.4292\/wjgpt.v6.i4.137","article-title":"Mesalazine preparations for the treatment of ulcerative colitis: are all created equal?","volume":"4","author":"Ye","year":"2015","journal-title":"World J Gastrointest Pharmacol Ther"},{"key":"2024103012365911000_jphp12928-cit-0179","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1111\/j.1365-2125.1987.tb03061.x","article-title":"Release of 5-aminosalicylic acid from Pentasa during normal and accelerated intestinal transit time","volume":"3","author":"Christensen","year":"1987","journal-title":"Br J Clin Pharmacol"},{"key":"2024103012365911000_jphp12928-cit-0180","first-page":"52","article-title":"The value of in vitro dissolution in drug development: a position paper from the Aaps in vitro release and dissolution focus group","volume":"33","author":"Cheng Tong","year":"2009","journal-title":"Pharm Technol"},{"key":"2024103012365911000_jphp12928-cit-0181","first-page":"109","article-title":"In vitro-in vivo Pharmacokinetic correlation model for quality assurance of antiretroviral drugs","volume":"3","author":"Rojas Gomez","year":"2015","journal-title":"Colomb Med (Cali)"},{"key":"2024103012365911000_jphp12928-cit-0182","doi-asserted-by":"crossref","first-page":"S73","DOI":"10.1016\/S0928-0987(00)00181-0","article-title":"In vitro-in vivo correlations for lipophilic, poorly water-soluble drugs","volume":"11","author":"Dressman","year":"2000","journal-title":"Eur J Pharm Sci"},{"key":"2024103012365911000_jphp12928-cit-0183","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1016\/j.ejps.2013.09.006","article-title":"Quantitative prediction of formulation-specific food effects and their population variability from in vitro data with the physiologically-based ADAM model: a case study using the BCS\/BDDCS class II drug nifedipine","volume":"57","author":"Patel","year":"2014","journal-title":"Eur J Pharm Sci"},{"key":"2024103012365911000_jphp12928-cit-0184","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1016\/j.ejpb.2010.05.009","article-title":"Forecasting in vivo oral absorption and food effect of micronized and nanosized aprepitant formulations in humans","volume":"1","author":"Shono","year":"2010","journal-title":"Eur J Pharm Biopharm"},{"key":"2024103012365911000_jphp12928-cit-0185","doi-asserted-by":"crossref","first-page":"937","DOI":"10.1111\/jphp.12059","article-title":"Coupling biorelevant dissolution methods with physiologically based pharmacokinetic modelling to forecast in-vivo performance of solid oral dosage forms","volume":"7","author":"Otsuka","year":"2013","journal-title":"J Pharm Pharmacol"},{"key":"2024103012365911000_jphp12928-cit-0186","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/j.ejps.2006.09.004","article-title":"A novel dissolution method relevant to intestinal release behaviour and its application in the evaluation of modified release mesalazine products","volume":"1","author":"Schellekens","year":"2007","journal-title":"Eur J Pharm Sci"},{"key":"2024103012365911000_jphp12928-cit-0187","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1016\/j.jddst.2014.12.002","article-title":"A dynamic in vitro model to evaluate the intestinal release behaviour of modified-release corticosteroid products","volume":"25","author":"Goyanes","year":"2015","journal-title":"J Drug Deliv Sci Technol"},{"key":"2024103012365911000_jphp12928-cit-0188","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1016\/j.ijpharm.2011.02.061","article-title":"Comparison of in vitro and in vivo performance of a colonic delivery system","volume":"1\u20132","author":"Ahmed","year":"2011","journal-title":"Int J Pharm"},{"key":"2024103012365911000_jphp12928-cit-0189","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1211\/0022357056172","article-title":"Site-specific delivery of anti-inflammatory drugs in the gastrointestinal tract: an in-vitro release model","volume":"6","author":"Klein","year":"2005","journal-title":"J Pharm Pharmacol"},{"key":"2024103012365911000_jphp12928-cit-0190","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1016\/j.ijpharm.2009.08.003","article-title":"Physiological bicarbonate buffers: stabilisation and use as dissolution media for modified release systems","volume":"1\u20132","author":"Fadda","year":"2009","journal-title":"Int J Pharm"},{"key":"2024103012365911000_jphp12928-cit-0191","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1016\/j.ejps.2015.03.012","article-title":"A novel dissolution method for evaluation of polysaccharide based colon specific delivery systems: a suitable alternative to animal sacrifice","volume":"73","author":"Singh","year":"2015","journal-title":"Eur J Pharm Sci"},{"key":"2024103012365911000_jphp12928-cit-0192","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1007\/BF00228615","article-title":"Development of a 5-step multi-chamber reactor as a simulation of the human intestinal microbial ecosystem","volume":"2","author":"Molly","year":"1993","journal-title":"Appl Microbiol Biotechnol"},{"key":"2024103012365911000_jphp12928-cit-0193","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1007\/s002530051622","article-title":"A computer-controlled system to simulate conditions of the large intestine with peristaltic mixing, water absorption and absorption of fermentation products","volume":"1","author":"Minekus","year":"1999","journal-title":"Appl Microbiol Biotechnol"},{"key":"2024103012365911000_jphp12928-cit-0194","doi-asserted-by":"crossref","first-page":"1008","DOI":"10.1111\/j.2042-7158.2012.01538.x","article-title":"A mechanistic pharmacokinetic model to assess modified oral drug bioavailability post bariatric surgery in morbidly obese patients: interplay between CYP3A gut wall metabolism, permeability and dissolution","volume":"7","author":"Darwich","year":"2012","journal-title":"J Pharm Pharmacol"},{"key":"2024103012365911000_jphp12928-cit-0195","first-page":"e47","article-title":"Evaluation of an in Silico PBPK post-bariatric surgery model through simulating oral drug bioavailability of atorvastatin and cyclosporine","volume":"6","author":"Darwich","year":"2013","journal-title":"CPT Pharmacometrics Syst Pharmacol"}],"container-title":["Journal of Pharmacy and Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fjphp.12928","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/academic.oup.com\/jpp\/article-pdf\/71\/4\/674\/60224059\/jphp12928.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jpp\/article-pdf\/71\/4\/674\/60224059\/jphp12928.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,7,4]],"date-time":"2025-07-04T11:17:16Z","timestamp":1751627836000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jpp\/article\/71\/4\/674\/6122203"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,4,1]]},"references-count":195,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2019,4,1]]},"published-print":{"date-parts":[[2019,4,1]]}},"URL":"https:\/\/doi.org\/10.1111\/jphp.12928","relation":{},"ISSN":["2042-7158","0022-3573"],"issn-type":[{"value":"2042-7158","type":"electronic"},{"value":"0022-3573","type":"print"}],"subject":[],"published-other":{"date-parts":[[2019,4]]},"published":{"date-parts":[[2019,4,1]]}}}